Hot Picks: Biotech stocks to watch as Phase III data and FDA decisions near [BNN Bloomberg (Canada)]
United Therapeutics Corporation (UTHR)
Last united therapeutics corporation earnings: 4/29 06:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.unither.com/investor-relations
Company Research
Source: BNN Bloomberg
One analyst is highlighting three companies with upcoming catalysts in seizures, idiopathic pulmonary fibrosis and Alzheimer's agitation. BNN Bloomberg spoke with Joe Thome, senior research analyst, biotech at TD Cowen, about his top picks in the sector and the milestones he believes could drive share performance this year. Key Takeaways Xenon Therapeutics is advancing azetukalner, a potassium channel opener, with Phase III data expected in focal onset seizures and potential upside if results confirm strong seizure-reduction trends. About 30 per cent of focal onset seizure patients continue to experience refractory seizures, underscoring demand for once-daily treatments with limited drug interactions. United Therapeutics' inhaled therapy Tyvaso is expanding beyond pulmonary hypertension into idiopathic pulmonary fibrosis, a market with significant unmet need and multibillion-dollar revenue potential. Existing IPF therapies are associated with gastrointestinal side effects,
Show less
Read more
Impact Snapshot
Event Time:
UTHR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
UTHR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
UTHR alerts
High impacting United Therapeutics Corporation news events
Weekly update
A roundup of the hottest topics
UTHR
News
- United Therapeutics (NASDAQ:UTHR) had its "buy" rating reaffirmed by analysts at UBS Group AG.MarketBeat
- United Therapeutics Corporation to Report Fourth Quarter and Full Year 2025 Financial Results Before the Market Opens on Wednesday, February 25, 2026 [Yahoo! Finance]Yahoo! Finance
- United Therapeutics Corporation to Report Fourth Quarter and Full Year 2025 Financial Results Before the Market Opens on Wednesday, February 25, 2026Business Wire
- United Therapeutics: In Progress -- New Organs For Old At Scale [Seeking Alpha]Seeking Alpha
- Hot Picks: Small-cap pharma stocks in focus as key drug approvals near [BNN Bloomberg (Canada)]BNN Bloomberg
UTHR
Earnings
- 10/29/25 - Beat
UTHR
Sec Filings
- 2/19/26 - Form 4
- 2/19/26 - Form 144
- 2/18/26 - Form 4
- UTHR's page on the SEC website